Home › Steatotic Liver Disease
Steatotic Liver Disease clinical trials recruiting in the U.S.
65 studies for Steatotic Liver Disease are recruiting participants at sites across the United States.
Steatotic liver disease, formerly called fatty liver disease, happens when too much fat builds up in your liver. Learn about the causes and treatments.
Cities with the most studies
- San Antonio, TX17 studies
- Miami, FL15 studies
- New York City, NY15 studies
- San Diego, CA14 studies
- Houston, TX13 studies
- Austin, TX12 studies
- Richmond, VA12 studies
- Chandler, AZ10 studies
- Dallas, TX9 studies
- Tucson, AZ9 studies
- Hialeah, FL9 studies
- Orlando, FL9 studies
- Pasadena, CA8 studies
- Los Angeles, CA8 studies
- Rochester, MN8 studies
- Dayton, OH8 studies
- Durham, NC8 studies
- New Orleans, LA8 studies
- Seattle, WA7 studies
- Las Vegas, NV7 studies
- Akron, OH7 studies
- Round Rock, TX7 studies
- Parma, OH7 studies
- Topeka, KS7 studies
- St. Louis, MO7 studies
- Washington, DC7 studies
- Ocala, FL7 studies
- Brownsville, TX7 studies
- Little Rock, AR7 studies
- Lancaster, CA7 studies
- Waco, TX6 studies
- Chicago, IL6 studies
- Cape Coral, FL6 studies
- Peoria, AZ6 studies
- Fayetteville, NC6 studies
- Sarasota, FL6 studies
- Fort Worth, TX6 studies
- Sandy Springs, GA6 studies
- Indianapolis, IN6 studies
- Sugar Land, TX6 studies
By state
- Alabama4 studies
- Arizona13 studies
- Arkansas7 studies
- California20 studies
- Colorado6 studies
- Connecticut5 studies
- Florida19 studies
- Georgia8 studies
- Illinois6 studies
- Indiana9 studies
- Iowa4 studies
- Kansas7 studies
- Kentucky4 studies
- Louisiana11 studies
- Maryland8 studies
- Massachusetts9 studies
- Michigan8 studies
- Minnesota9 studies
- Mississippi5 studies
- Missouri12 studies
- Nevada7 studies
- New Jersey6 studies
- New Mexico3 studies
- New York16 studies
- North Carolina12 studies
- Ohio15 studies
- Pennsylvania5 studies
- Rhode Island3 studies
- South Carolina5 studies
- Tennessee7 studies
- Texas20 studies
- Utah5 studies
- Virginia14 studies
- Washington7 studies
Recently updated studies
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 28, 2026 · NCT05832229Early Tracking of Childhood Health Determinants (ETCHED) Study
RecruitingObservational studyHealthy volunteers welcome
1 Day – 99 Years · All sexes · Updated Sep 28, 2026 · NCT03481829A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT05519475Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
RecruitingPhase 2
Ages 5 to 16 · All sexes · Updated Sep 22, 2026 · NCT06133101A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Sep 21, 2026 · NCT06528314A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 18, 2026 · NCT07701993A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 18, 2026 · NCT07704892A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 17, 2026 · NCT07221188Fully Automated High-Throughput Quantitative MRI of the Liver
RecruitingObservational studyHealthy volunteers welcome
Ages 7 and older · All sexes · Updated Sep 16, 2026 · NCT05294471A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 9, 2026 · NCT07288138A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 3, 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Sep 3, 2026 · NCT06318169Human Models of Selective Insulin Resistance: Alpelisib, Part I
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 70 · All sexes · Updated Aug 24, 2026 · NCT06354088Quantifying Hepatic Mitochondrial Fluxes in Humans
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Aug 17, 2026 · NCT05305287InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
RecruitingObservational studyHealthy volunteers welcome
All ages · All sexes · Updated Aug 17, 2026 · NCT05463796Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis
RecruitingHealthy volunteers welcome
Ages 25 to 55 · All sexes · Updated Aug 12, 2026 · NCT06993454A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Aug 10, 2026 · NCT07527910Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
RecruitingPhase 2Healthy volunteers welcome
Ages 18 to 100 · All sexes · Updated Aug 10, 2026 · NCT03884075Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
RecruitingHealthy volunteers welcome
Ages 18 to 70 · All sexes · Updated Aug 6, 2026 · NCT06335771Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease
Recruiting
Ages 30 to 70 · All sexes · Updated Aug 6, 2026 · NCT07646197Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 70 · All sexes · Updated Aug 6, 2026 · NCT06571474A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Aug 3, 2026 · NCT06613698Fibrosis Lessens After Metabolic Surgery
RecruitingPhase 4Healthy volunteers welcome
Ages 18 to 75 · All sexes · Updated Jul 31, 2026 · NCT06374875Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
RecruitingObservational study
Ages 12 to 18 · All sexes · Updated Jul 30, 2026 · NCT04634643From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.